About
ParcelBio is developing transformative mRNA medicines using its proprietary APEXm™ platform, engineered for significantly higher potency and durability than existing mRNA technologies. This platform enables a new class of therapies, including in vivo CAR-T for autoimmune diseases and oncology, and durable delivery of therapeutic proteins. ParcelBio serves patients by creating advanced mRNA medicines that can reach therapeutic thresholds previously unattainable.
Tags
Total Employees
6
Current headcount
Performance
Company Timeline
No timeline data for this period
Discussion (0)
Join the discussion
No comments yet. Be the first to share your thoughts!
Frequently Asked Questions
What does ParcelBio do?
ParcelBio is developing transformative mRNA medicines using its proprietary APEXm™ platform, engineered for significantly higher potency and durability than existing mRNA technologies. This platform enables a new class of therapies, including in vivo CAR-T for autoimmune diseases and oncology, and durable delivery of therapeutic proteins. ParcelBio serves patients by creating advanced mRNA medicines that can reach therapeutic thresholds previously unattainable.
How much funding has ParcelBio raised?
ParcelBio has raised a total of $110M in funding. The most recent round on record is Series A.
Where is ParcelBio headquartered?
ParcelBio is headquartered in San Francisco, California, USA.
When was ParcelBio founded?
ParcelBio was founded in 2023.
What industry does ParcelBio operate in?
ParcelBio operates in Biotechnology, Pharmaceuticals, HealthTech, Artificial Intelligence, Biotech, Drug Discovery.
How many employees does ParcelBio have?
ParcelBio has approximately 6 people on record.